The latest biotech news

novo holdings antibiotic resistance fight 1

News and Trends 28 Feb 2018

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […]

February 28, 2018 - 3 minutesmins - By Alex Dale

News and Trends 28 Feb 2018

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […]

February 28, 2018 - 4 minutesmins - By Alex Dale

News and Trends 28 Feb 2018

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […]

February 28, 2018 - 8 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

Update: Deinove is About to Launch a Bacterial Anti-Aging Skincare Product

Update (27/2/2018): Deinove produced the first industrial batch of its carotenoid product and plans to launch the cosmetic skincare treatment at the In-Cosmetics tradeshow in Amsterdam this coming April. The news resulted in a soaring 57% increase of Deinove’s stock price. Originally published on 19/12/2017 Deinove has set the wheels in motion as it looks […]

February 27, 2018 - 2 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy

Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […]

February 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 27 Feb 2018

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

DBV Technologies’ candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin patch, Viaskin, as an immunotherapy for the treatment peanut, egg, and milk allergies. In a Phase II study, Viaskin Milk has desensitized children between the […]

February 27, 2018 - 3 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and efficiency of drug development. Pelago, a Karolinska Institute spin-off, studies the interactions between a drug and its target to make the drug development process faster and more efficient. The Cellular Thermal Shift Assay (CETSA) was developed by Pelago to examine the […]

February 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 26 Feb 2018

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […]

February 26, 2018 - 3 minutesmins - By Alexander Burik

multiple sclerosis antibody CIDP geneuro 1

News and Trends 26 Feb 2018

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

The FDA has awarded Orphan Drug Designation to GeNeuro’s antibody for the treatment of a rare autoimmune disease following promising Phase IIb results in multiple sclerosis patients. GeNeuro develops therapies targeting factors encoded by human endogenous retroviruses that are implicated in neurological and autoimmune disorders. The biotech’s drug, GNbAC1, which is being developed for multiple […]

February 26, 2018 - 2 minutesmins - By Alex Dale

News and Trends 26 Feb 2018

This Oral Vaccine for Typhoid Raises €8M from International Investors

Prokarium has raised $10M (€8M) from Saudi, Swedish and Korean investors to support the clinical development of its oral vaccines for infectious diseases like typhoid. Since its foundation in 2012, Prokarium has been working on oral vaccines and it has developed a delivery platform that can be applied to any antigen used for vaccination. The biotech has […]

February 26, 2018 - 3 minutesmins - By Alex Dale

News and Trends 23 Feb 2018

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […]

February 23, 2018 - 3 minutesmins - By Alexander Burik

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Update: Deinove is About to Launch a Bacterial Anti-Aging Skincare Product

Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy

DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial

AstraZeneca Collaborates With Swedish Biotech To Speed Up Drug Development

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

This Multiple Sclerosis Drug Could Help to Fight Another Autoimmune Disease

This Oral Vaccine for Typhoid Raises €8M from International Investors

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!